|
WO2021080968A1
|
|
Delivery systems and method using cannabinoids for treatment of inflammatory disorders
|
|
WO2021067816A1
|
|
Methods for assessing the risk of developing active tuberculosis
|
|
WO2021067633A2
|
|
Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
|
|
WO2021050371A1
|
|
Biotin synthases for efficient production of biotin
|
|
WO2021041852A1
|
|
Glycosylated diphyllin as a broad-spectrum antiviral agent against zika virus and covid-19
|
|
WO2020247723A1
|
|
Rapid synthesis of metal nanoparticles
|
|
WO2020243078A1
|
|
Antibody-based method to identify, purify, and manipulate cell types and processes
|
|
WO2020236907A1
|
|
Compounds and methods for treatment of bacterial infections
|
|
WO2020219353A1
|
|
Red blood cells expressing von willebrand factor protease and methods of use thereof
|
|
WO2020191181A1
|
|
Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
|
|
WO2020176501A1
|
|
Compounds useful for inhibiting raf dimers
|
|
US2020270349A1
|
|
Methods of treatment by targeting vcam1 and maea
|
|
WO2020142677A1
|
|
Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
|
|
WO2020132654A1
|
|
Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof
|
|
WO2020102779A1
|
|
MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
|
|
WO2020086688A1
|
|
Fidgetin-like 2 sirna-enhanced poloxamer-based hydrogel for wound healing
|
|
WO2020081820A1
|
|
Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
|
|
WO2020077024A1
|
|
Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
|
|
WO2020068615A1
|
|
Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
|
|
WO2020068500A1
|
|
Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof
|
